News

Interactive Strength Inc. (Nasdaq:TRNR) Enters the Medical channel for the first time by Exhibiting FORME at APTA Private Practice Annual Conference on October 9-12

The medical channel, and specifically physical therapy, is a new channel for FORMEWOODWAY has been in the medical channel for…

1 year ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT /…

1 year ago

PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA

TORONTO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a…

1 year ago

Parexel’s Teri Karcher Named to 2024 PharmaVoice 100

Chief Drug Development Officer and Executive Vice President, Head of Launch Excellence recognized for pioneering leadership in drug development DURHAM,…

1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

SARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments…

1 year ago

Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals

AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally available…

1 year ago

Autonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

Live webcast fireside chat on Tuesday, October 15th at 2:30 PM ET THE WOODLANDS, TX, Oct. 08, 2024 (GLOBE NEWSWIRE)…

1 year ago

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

DENVER , Oct. 08, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing…

1 year ago

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to…

1 year ago

Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing…

1 year ago